Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis, a Randomized Controlled Trial
Along with the current clinical trial, the efficacy and safety of a 20 mg rivaroxaban administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral heamoragic complications.
• Patients aged 18 and above
• New diagnosis of symptomatic cerebral venous thrombosis as confirmed on CT/CT venogram or MRI/MR venogram
• Ability to randomize within 14 days of neuroimaging-confirmed diagnosis
• The treating clinician is of the opinion that the patient is appropriate for oral anticoagulation as per the standard of care
• The patient or legally authorized representative is able to give written informed consent